NCT06198387View on ClinicalTrials.gov

Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2028

Conditions
Oligo-metastatic Prostate Carcinoma
Interventions
RADIATION

hormone and RT

The patients will receive a two-year course of androgen deprivation therapy (ADT) in combination with abiraterone, along with synchronous metastasis-directed radiation and prostate radiotherapy(RT).

DRUG

ADT combined with abiraterone

The patients will receive a two-year course of ADT combined with abiraterone.

Trial Locations (1)

200433

Shanghai Changhai Hospital, Shanghai

All Listed Sponsors
lead

Changhai Hospital

OTHER

NCT06198387 - Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter